Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18659849 | 0.87 | PDE10A (0.48) | DDAH1PDE10ASCN10AKCNH2 | |
| SCHEMBL12190473 | 0.87 | SCN10A (0.58) | DDAH1GAAHTTPDE10ASCN10A | |
| SCHEMBL10284701 | 0.85 | DDAH1 (0.53) | DDAH1GAAHTTPDE10AKIF11 | |
| SCHEMBL10183575 | 0.85 | SCN10A (0.48) | DDAH1PDE10ASCN10AKCNH2KIF11 | |
| SCHEMBL10202450 | 0.83 | CYP2C19 (0.45) | DDAH1PDE10ASCN10AKCNH2KIF11 | |
| SCHEMBL9286654 | 0.79 | RAD52 (0.47) | PDE10ASCN10A | |
| SCHEMBL9886999 | 0.79 | PDE10A (0.47) | PDE10ASCN10AKCNH2HDAC6 | |
| Hydrochloric Acid SCHEMBL9285292 | 0.78 | PDE10A (0.46) | PDE10AHDAC6 | |
| SCHEMBL12402382 | 0.78 | SCN10A (0.51) | PDE10ASCN10AKCNH2KIF11HDAC6 | |
| SCHEMBL846855 | 0.77 | SCN10A (0.58) | SCN10AKCNH2KIF11HDAC6METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604295-A1 | SILICON-CONTAINING COMPOUND FOR RESISTANCE TO HEPATITIS C VIRUS INFECTION | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-02-05 | — | — | EP | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDAH1 1418/4885GAA 223/4885HTT 1821/4885 |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | DDAH1 496/4885GAA 2923/4885HTT 4308/4885 |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | DDAH1 480/4885GAA 4034/4885HTT 3670/4885 |
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDAH1 1418/4885GAA 223/4885HTT 1821/4885 |
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDAH1 1418/4885GAA 223/4885HTT 1821/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDAH1 1418/4885GAA 223/4885HTT 1821/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDAH1 1418/4885GAA 223/4885HTT 1821/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDAH1 1418/4885GAA 223/4885HTT 1821/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDAH1 1418/4885GAA 223/4885HTT 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.